Amazon is not a health care company. It does not treat patients, sell insurance, or make prescription drugs. And although it has revolutionized modern commerce, it has not discovered a cure for cancer.

And yet, when the company announced a partnership with JPMorgan and Berkshire Hathaway to fix health care for employees last Tuesday, a $3.5 trillion industry began to tremble. Leading health stocks nosedived, losing $69 billion in value before the ink was dry on a 400-word press release that provided no detail on what Amazon will do in health care, or how it will do it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy